Data pattern analysis for the individualised pretherapeutic identification of high-risk diffuse large B-cell lymphoma (DLBCL) patients by cytomics

Cytometry Part A

Volumn 59, Issue 2, 2004, Pages 232-236

  Valet, Günter K ^a   Hoeffkes, Heinz Gert ^b  

^a MAX PLANCK INSTITUTE OF BIOCHEMISTRY   (Germany)

^b KLINIKUM FULDA   (Germany)

Author keywords

Cytomics; Data pattern classification; Data sieving; Diffuse large B cell lymphoma; DLBCL; Predictive medicine

Indexed keywords

ARTICLE; CANCER CLASSIFICATION; CANCER SURVIVAL; CLINICAL TRIAL; CYTOMETRY; DATA ANALYSIS; DIFFUSE LARGE B CELL LYMPHOMA; DNA MICROARRAY; GENE EXPRESSION; HIGH RISK PATIENT; HUMAN; LARGE CELL LYMPHOMA; LYMPHOCYTE; META ANALYSIS; PERFORMANCE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; SYSTEMATIC REVIEW; VALIDATION PROCESS;

EID: 2942555469     PISSN: 15524922     EISSN: None     Source Type: Journal    
DOI: 10.1002/cyto.a.20057     Document Type: Article

References (9)

1. Kaplan J. Genomics and medicine: hopes and challenges. Gene Ther 2002;9:658-661.
2. Lindpaintner K. Pharmacogenetics and the future of medical practice. J Mol Med 2003;81:141-153.
3. Repp R, Schaekel U, Helm G, Thiede C, Soucek S, Pascheberg U, Wandt H, Aulitzky W, Bodenstein H, Sonnen R, Link H, Ehninger G, Gramatzki M, AML-SHG study group. Immunophenotyping as an independent factor for risk stratification in AML. Cytometry 2003;53B: 11-19.
4. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 1998;95:1486-1488.
5. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, Gascoyne RD, Muller-Hermelink HK, Smeland EB, Giltnane JM, Hurt EM, Zhao H, Averett L, Yang L, Wilson WH, Jaffe ES, Simon R, Klausner RD, Powell J, Duffey PL, Longo DL, Greiner TC, Weisenburger DD, Sanger WG, Dave BJ, Lynch JC, Vose J, Armitage JO, Montserrat E, Lopez-Guillermo A, Grogan TM, Miller TP, LeBlanc M, Ott G, Kvaloy S, Delabie J, Holte H, Krajci P, Stokke T, Staudt LM; Lymphoma/Leukemia Molecular Profiling Project. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002;346:1937-1947.
6. Ntzani EE, Ioannidis JPA. Predictive ability of DNA microarrays for cancer outcomes and correlates: an empirical assessment. Lancet 2003;362:1439-1444.
7. Valet G. Predictive medicine by cytomics: potential and challenges. J Biol Regul Homeost Agents 2002;16:164-167.
8. Lymphoma/Leukemia Molecular Profiling Project. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. Bethesda, MD: National Institutes of Health. (http://llmpp.nih.gov/DLBCL).
9. Valet G, Repp R, Link H, Ehninger G, Gramatzki M, SHG-AML study group. Pretherapeutic identification of high-risk acute myeloid leukemia (AML) patients from immunophenotypic, cytogenetic, and clinical parameters. Cytometry 2003;53B:4-10.